Teva Pharmaceutical Industries Limited (0LER.L)
| Previous close | 7.09 |
| Open | 7.22 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 7.08 - 7.16 |
| 52-week range | 7.08 - 11.25 |
| Volume | |
| Avg. volume | 13,204 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.29 |
Business WireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
REYKJAVIK, Iceland & PARSIPPANY, N.J., April 16, 2024--Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under
Business WireTeva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
TEL AVIV, Israel & PARSIPPANY, N.J., April 16, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body
- Yahoo Finance Video
Israeli economy has proven to thrive despite crisis: Expert
Over the weekend, Iran launched a direct attack on Israel. Although Israel successfully intercepted the drones and missiles, the potential for an Israeli retaliation remains uncertain. David Blumberg of Blumberg Capital joins Yahoo Finance to discuss the state of the Israeli economy in light of these developments. Blumberg claims that Israelis are "somewhat used to these types of things." Blumberg notes that over the past 25 years, the country has weathered numerous crises, but has achieved consistent growth. He points to Israel's GDP per capita of $54,000, which exceeds that of some of the world's largest economies, as evidence of the economy's ability to "thrive despite and through downturns." For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
